DNLI
Price
$20.11
Change
+$1.11 (+5.84%)
Updated
Dec 4, 04:59 PM (EDT)
Capitalization
2.79B
88 days until earnings call
Intraday BUY SELL Signals
MIRM
Price
$71.27
Change
+$0.28 (+0.39%)
Updated
Dec 4, 02:40 PM (EDT)
Capitalization
3.65B
97 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNLI vs MIRM

Header iconDNLI vs MIRM Comparison
Open Charts DNLI vs MIRMBanner chart's image
Denali Therapeutics
Price$20.11
Change+$1.11 (+5.84%)
Volume$52.76K
Capitalization2.79B
Mirum Pharmaceuticals
Price$71.27
Change+$0.28 (+0.39%)
Volume$140
Capitalization3.65B
DNLI vs MIRM Comparison Chart in %
DNLI
Daily Signal:
Gain/Loss:
MIRM
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DNLI vs. MIRM commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and MIRM is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (DNLI: $19.00 vs. MIRM: $70.99)
Brand notoriety: DNLI and MIRM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 95% vs. MIRM: 109%
Market capitalization -- DNLI: $2.79B vs. MIRM: $3.65B
DNLI [@Biotechnology] is valued at $2.79B. MIRM’s [@Biotechnology] market capitalization is $3.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileMIRM’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • MIRM’s FA Score: 1 green, 4 red.
According to our system of comparison, MIRM is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 6 TA indicator(s) are bullish while MIRM’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 6 bullish, 4 bearish.
  • MIRM’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than MIRM.

Price Growth

DNLI (@Biotechnology) experienced а -2.06% price change this week, while MIRM (@Biotechnology) price change was -2.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.21%. For the same industry, the average monthly price growth was +5.86%, and the average quarterly price growth was +56.03%.

Reported Earning Dates

DNLI is expected to report earnings on Mar 02, 2026.

MIRM is expected to report earnings on Mar 11, 2026.

Industries' Descriptions

@Biotechnology (+1.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MIRM($3.65B) has a higher market cap than DNLI($2.79B). MIRM YTD gains are higher at: 71.681 vs. DNLI (-6.771). MIRM has higher annual earnings (EBITDA): -18.79M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. MIRM (305M). DNLI has less debt than MIRM: DNLI (46.6M) vs MIRM (319M). MIRM has higher revenues than DNLI: MIRM (429M) vs DNLI (0).
DNLIMIRMDNLI / MIRM
Capitalization2.79B3.65B76%
EBITDA-521.52M-18.79M2,775%
Gain YTD-6.77171.681-9%
P/E RatioN/AN/A-
Revenue0429M-
Total Cash899M305M295%
Total Debt46.6M319M15%
FUNDAMENTALS RATINGS
DNLI vs MIRM: Fundamental Ratings
DNLI
MIRM
OUTLOOK RATING
1..100
2063
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
54
Fair valued
PROFIT vs RISK RATING
1..100
1007
SMR RATING
1..100
9695
PRICE GROWTH RATING
1..100
4644
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MIRM's Valuation (54) in the null industry is somewhat better than the same rating for DNLI (93) in the Biotechnology industry. This means that MIRM’s stock grew somewhat faster than DNLI’s over the last 12 months.

MIRM's Profit vs Risk Rating (7) in the null industry is significantly better than the same rating for DNLI (100) in the Biotechnology industry. This means that MIRM’s stock grew significantly faster than DNLI’s over the last 12 months.

MIRM's SMR Rating (95) in the null industry is in the same range as DNLI (96) in the Biotechnology industry. This means that MIRM’s stock grew similarly to DNLI’s over the last 12 months.

MIRM's Price Growth Rating (44) in the null industry is in the same range as DNLI (46) in the Biotechnology industry. This means that MIRM’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as MIRM (100) in the null industry. This means that DNLI’s stock grew similarly to MIRM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIMIRM
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
69%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
68%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 11 days ago
75%
Declines
ODDS (%)
Bearish Trend 22 days ago
82%
Bearish Trend 15 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 7 days ago
68%
Bearish Trend 2 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signal:
Gain/Loss:
MIRM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JUSMX20.060.34
+1.72%
JPMorgan US Small Company R6
MMMSX23.290.27
+1.17%
Victory Integrity Small/Mid-Cap Value Mb
TEMWX19.950.11
+0.55%
Templeton World A
ISCSX17.230.09
+0.53%
VY® Columbia Contrarian Core S
MGRAX49.280.12
+0.24%
MFS International Growth A

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with RGNX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+6.50%
RGNX - DNLI
56%
Loosely correlated
+5.49%
NRIX - DNLI
54%
Loosely correlated
+2.94%
ELVN - DNLI
54%
Loosely correlated
+2.14%
SYRE - DNLI
53%
Loosely correlated
+13.38%
BEAM - DNLI
53%
Loosely correlated
+14.42%
More

MIRM and

Correlation & Price change

A.I.dvisor indicates that over the last year, MIRM has been loosely correlated with XERS. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MIRM jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MIRM
1D Price
Change %
MIRM100%
+1.59%
XERS - MIRM
53%
Loosely correlated
+4.02%
DNLI - MIRM
43%
Loosely correlated
+6.50%
TARS - MIRM
42%
Loosely correlated
+3.07%
IRON - MIRM
41%
Loosely correlated
+2.96%
OCUL - MIRM
41%
Loosely correlated
+1.87%
More